Verified By June 9, 2023
Verified by: Dr. Punit Jain, Lead & Consultant BMT Program, Consultant Haematologist & Hemato-Oncologist, Apollo Cancer Centres, Navi Mumbai
In the union budget of FY 2023-24, the finance minister announced the launch of a mission to eliminate Sickle Cell Anaemia (SCA) by 2047 – the 100th year of India’s independence. The mission entails focusing on creating awareness and universal screening for those in the zero to forty year’s age group.
What is Sickle Cell Anaemia (SCA)?
Sickle Cell Anaemia (SCA) is an inherited (acquired through parents) red blood cell disorder that affects haemoglobin. Normally, red blood cells are disc-shaped, enabling easy passage through the blood vessels. However, in people with SCA, the red blood cells have a tendency to become crescent- or “sickle”-shaped due to a genetic mutation making them sticky and rigid, thus, restricting blood from reaching different parts of the body. Diagnosis is usually done through a combination of blood tests.
What are the symptoms of SCA?
How is SCA treated?
Management of sickle cell anaemia is usually aimed at avoiding pain episodes, relieving symptoms, and preventing complications. Treatments include medications like hydroxyurea, and folate, timely vaccinations and blood transfusions when indicated. Blood transfusions are used to increase the number of normal red blood cells, which helps reduce symptoms and prevent complications such as stroke. Novel research has helped identify medications like L-glutamine, Crizanlizumab and Voxelotor, which help to reduce painful crises.
A stem cell transplant (BMT) can cure SCA in children and teenagers. The procedure involves replacing the affected bone marrow with healthy bone marrow obtained from a matched donor, such as a sibling or unrelated donor and sometimes either parent can be a haploidentical donor who may have a sickle cell trait and not a full disease. Although curative, BMT in sickle cell disease has its fair share of risks; hence the treatment is only recommended to people, usually children, who have significant complications of SCA. Clinical trials are also ongoing to address gene correction in SCA.
Apollo Hospitals Group, India, has performed over 2500 bone marrow transplants with good outcomes and remains a trusted name in the field of Bone Marrow Transplant (BMT) for both domestic and international patients. Apollo group of hospitals have a highly qualified multidisciplinary BMT team with stringent infection control norms which is extremely critical for BMT patients. Apollo also offers genetic counselling for early diagnosis and prenatal evaluation of parents with sickle cell trait or a homozygous disease. Several successful pregnancies in women with sickle cell disease have also been conducted successfully at Apollo hospitals.
A combined approach for an early diagnosis with optimum treatment remains the key to managing this disease and ensuring better treatment outcomes for people with SCA!
Call 022 6280 6280 for an appointment.